Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316135 | 1.00 | EPHX2 (0.43) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL4988276 | 1.00 | EPHX2 (0.43) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL2842255 | 1.00 | EPHX2 (0.43) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL1933741 | 1.00 | EPHX2 (0.43) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL16678151 | 0.82 | EPHX2 (0.44) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL7080802 | 0.82 | EPHX2 (0.44) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL924280 | 0.82 | EPHX2 (0.44) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL7158785 | 0.82 | EPHX2 (0.44) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL6831561 | 0.82 | EPHX2 (0.44) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL6043241 | 0.82 | EPHX2 (0.44) | EPHX2MAPTMAPK1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979335-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | claimed |
| WO-2007082808-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | claimed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7345058-B2 | (1-Methyl-5-phenyl-1H-pyrazol-4-yl)-(trans-octahydro-isoquinolin-2-yl)methanone; 11 beta -hydroxysteroid dehydrogenase inhibitor; upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase); antidiabetic agent; type II diabetes mellitus and metabolic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20060223852-A1 | Pyrazoles | GILLESPIE PAUL | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223852-A1 | Pyrazoles | GPR119, PDK2, PC | EPHX2 3399/4885MAPT 3416/4885MAPK1 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.